Heiwa Real Estate REIT: Notice regarding revisions to operating status forecasts for the fiscal year ending 2025/5 (47th period) and the fiscal year ending 2025/11 (48th period)

JPX15:45 · Announcements

Heiwa Real Estate REIT: Notice regarding revisions to operating status forecasts for the fiscal year ending 2025/11 (48th term)

JPXApr 3 14:30 · Announcements

Heiwa A-REIT ETF Investment Corporation - Status of domestic Assets acquisition and transfer.

Heiwa A-REIT ETF Investment Corporation <8966> announced on the 25th that its asset management company, Heiwa Real Estate Asset Management, has decided to acquire and transfer domestic assets. This Trade, combined with this acquisition and transfer, aims to improve the quality and profitability of the portfolio. The property being acquired is "HF Meguro Gyotanzaka Residence" (Meguro Ward, Tokyo), with an intended acquisition price of 5.3 billion yen and a valuation amount of 6.3 billion yen. The date of the sales contract signing is February 25, 2025, and acquisition expected.

Fisco JapanFeb 26 08:52

Heiwa A-REIT ETF Investment Corporation - Revision of the Financial Estimates for the period ending in May 2025 (47th Term)

Heiwa A-REIT ETF Investment Corporation <8966> announced on the 25th that it has revised its Financial Estimates for the management situation of the May 2025 period (47th term: December 1, 2024 - May 31, 2025) as disclosed in the "Consolidated Financial Results for the Fiscal Year Ending November 2024" dated January 17, 2025. This revision is due to the decision to acquire the "HF Meguro Gyotoku Residence" and to transfer the "Kojimachi HF Building." According to the revised estimates, operating revenue has increased from the previous prediction of 8.108 billion yen to 9.236 billion yen, an increase of 11.

Fisco JapanFeb 26 08:52

Vital KSK, upward revision on March 25, ordinary profit 6.7 billion yen, up from 6.4 billion yen.

Vital KSK <3151> announced a revision of the financial estimates for the fiscal year ending March 2025. Revenue has been revised upwards from 590 billion yen to 600 billion yen, and ordinary profit increased from 6.4 billion yen to 6.7 billion yen. In the main Drug Distribution business, sales of newly developed products focusing on anticancer drugs and various Vaccines have increased, along with a rise in the sales of test kits and treatments due to the rapid spread of influenza this season, showing favorable performance. 【Positive Evaluation】 <2749> JPHD Revision | <7596> Uoriki

Fisco JapanFeb 26 04:57

Heiwa Real Estate REIT: Notice regarding revisions to operating status forecasts for the fiscal year ending 2025/5 (47th term)

JPXFeb 25 15:30 · Announcements